CASE STUDY: SEQIRUS
The world’s no.2 influenza vaccine provider
Seqirus, the world’s no.2 influenza vaccine provider, recently announced a £22.1 million investment for its site in Liverpool.
The company, which is part of global biotherapeutics leader CSL Limited, is developing a new £15.3 million manufacturing facility to support the production of influenza vaccines at its Liverpool site, complemented by a £6.8 million warehouse which opened in early 2017. The development paves the way for the future expansion of product manufacturing at the Liverpool site, which plays an important role in Seqirus’ global operations.